Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471672 | 1.00 | SRD5A2 (0.44) | SRD5A2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4470863 | 0.94 | KDM4E (0.46) | SRD5A2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4470867 | 0.94 | KDM4E (0.46) | SRD5A2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4483689 | 0.88 | SRD5A2 (0.42) | SRD5A2SRD5A1 | |
| SCHEMBL4483686 | 0.88 | SRD5A2 (0.42) | SRD5A2SRD5A1 | |
| SCHEMBL4476341 | 0.86 | SRD5A2 (0.48) | SRD5A2SRD5A1 | |
| SCHEMBL4476347 | 0.86 | SRD5A2 (0.48) | SRD5A2SRD5A1 | |
| SCHEMBL6358541 | 0.86 | SRD5A2 (0.48) | SRD5A2SRD5A1 | |
| SCHEMBL4472551 | 0.85 | SRD5A2 (0.44) | SRD5A2SRD5A1 | |
| SCHEMBL4472555 | 0.85 | SRD5A2 (0.44) | SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-20060281761-A1 | 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-12-14 | — | — | US | claimed |
| US-20050131005-A1 | 4-azasteroid derivatives as androgen receptor modulators | WANG JIABING (US) | 2005-06-16 | — | — | US | claimed |
| EP-1501512-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2003092588-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-13 | — | — | WO | claimed |
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20060281761-A1 | 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-12-14 | — | — | US | disclosed |
| US-20050131005-A1 | 4-azasteroid derivatives as androgen receptor modulators | WANG JIABING (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1501512-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003092588-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281761-A1 | 4-azasteroid derivatives as androgen receptor modulators | NR5A1, AR, NR3C1 | SRD5A2 9/4885KDM4E 604/4885ALDH1A1 1068/4885 |
| US-20050131005-A1 | 4-azasteroid derivatives as androgen receptor modulators | AR, NR5A1, NR3C1 | SRD5A2 9/4885KDM4E 573/4885ALDH1A1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.